Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Roxane Laboratories |
---|---|
Information provided by: | Roxane Laboratories |
ClinicalTrials.gov Identifier: | NCT00674310 |
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions using a single dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.
Condition | Intervention |
---|---|
Parkinson's Disease Restless Leg Syndrome |
Drug: Ropinirole Hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Bio-equivalence Study |
Official Title: | A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions |
Enrollment: | 29 |
Study Start Date: | February 2004 |
Study Completion Date: | February 2004 |
Primary Completion Date: | February 2004 (Final data collection date for primary outcome measure) |
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole tablets,0.25 mg, to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fed conditions using a single dose, randomized, 2-treatment, 2-period, 2-sequence cross-over design.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | SFB C Anapharm ( Richard Larouche, M.D. ) |
Study ID Numbers: | ROPI-T25-PVFD-1 |
Study First Received: | May 5, 2008 |
Last Updated: | May 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00674310 History of Changes |
Health Authority: | United States: Institutional Review Board |
Neurotransmitter Agents Ropinirole Ganglion Cysts Basal Ganglia Diseases Dyssomnias Central Nervous System Diseases Sleep Disorders Psychomotor Agitation Dopamine Agonists Brain Diseases |
Neurodegenerative Diseases Sleep Disorders, Intrinsic Dopamine Malnutrition Mental Disorders Parkinson Disease Movement Disorders Restless Legs Syndrome Dopamine Agents Parkinsonian Disorders |
Neurotransmitter Agents Ropinirole Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Basal Ganglia Diseases Sleep Disorders Antiparkinson Agents Neurodegenerative Diseases Brain Diseases Dopamine Agonists Sleep Disorders, Intrinsic Pathologic Processes Movement Disorders |
Mental Disorders Syndrome Therapeutic Uses Restless Legs Syndrome Disease Nervous System Diseases Parasomnias Dyssomnias Central Nervous System Diseases Pharmacologic Actions Parkinson Disease Dopamine Agents Parkinsonian Disorders Central Nervous System Agents |